Trial Profile

A Phase 2, Open-label, Multicenter Study Investigating RP2 Oncolytic Immunotherapy in Combination With Second-line Therapy in Patients With Locally Advanced Unresectable, Recurrent and/or Metastatic Hepatocellular Carcinoma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 02 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Durvalumab (Primary) ; RP 2 (Primary) ; RP 3 (Primary)
Indications Adenocarcinoma; Biliary cancer; Cholangiocarcinoma; Gallbladder cancer; Liver cancer
Focus Therapeutic Use
Sponsors Replimune

06 Nov 2025 According to a Replimune media release, data planned by the end of 2026.
06 Nov 2025 According to a Replimune media release, company expects to enroll its first patient in the fourth quarter of 2025 in a cohort evaluating RP2 in patients with biliary tract cancer.
05 Sep 2025 Planned number of patients changed from 30 to 60.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com